Bilateral jaw fracture after long term treatment with bisphosphonates. A case report.

  1. Cariati, Paolo 1
  2. Sánchez López, Darío 1
  3. Pérez de Perceval, Miguel 1
  4. Valencia, Alfredo 1
  5. Gracia Medina, Blas 1
  1. 1 Universidad de Granada
    info

    Universidad de Granada

    Granada, España

    ROR https://ror.org/04njjy449

Aldizkaria:
Actualidad médica

ISSN: 0365-7965

Argitalpen urtea: 2016

Liburukia: 101

Zenbakia: 798

Orrialdeak: 115-116

Mota: Artikulua

DOI: 10.15568/AM.2016.798.CC03 DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Actualidad médica

Garapen Iraunkorreko Helburuak

Laburpena

Bisphosphonates represent type of medication used for treating numerous pathologies. In fact, more and more clinicians utilize bisphosphonates for dealing oncological diseases, rheumatic pathologies and severe osteoporosis. Despite its benefits, various undesirable side effects have also been associated with the use of these drugs. For instance, patients who receive bisphosphonates present a greater risk of suffering osteonecrosis of jaw. Indeed, the possibility of experiencing this complication is around 0,812% when bisphosphonates are administered intravenously. In contrast, the risk is about 0,01% with oral administration. However, when a tooth extraction is carried out the risk rises to 0,34%. This report presents the case of a 66 years old woman who suffered a bilateral jaw fracture after prolonged treatment with bisphosphonates. Interestingly, no invasive dental procedures were referred by patient. The main aim of this paper is to focus the attention on the serious complications that this treatment may show in the long term.

Erreferentzia bibliografikoak

  • A.A. Polymeri, G.J. Kodovazenitis, A.D. Polymeris, M. Komboli. Bisphosphonates: Clinical Applications and Adverse Events in Dentistry. Oral Health Prev Dent. 2015; 13:289-99. doi: 10.3290/j.ohpd.a34370.
  • Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65:369- 76.
  • C. Walter, M.O. Klein, A. Pabst, B. Al-Nawas, H. Duschner, T. Ziebart. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig. 2010; 14:35- 41. doi: 10.1007/s00784-009-0266-4.
  • F.L Heggendorn, T.C. Leite, K.S. Cunha, A.S. Junior, L.S. Gonçalves, K.B. Da Costa, E.P. Dias. Bisphosphonate-related osteonecrosis of the jaws: Report of a case using conservative protocol. Spec Care Dentist. 2016; 36:43-7. doi: 10.1111/scd.12143.
  • F.R. Pires, A. Miranda, E.S. Cardoso, A.S. Cardoso, E.R. Fregnani, C.M. Pereira, M.E. Correa, J.P. lmeida , F. de A Alves , M.A. Lopes, O.P. De Almeida. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis. 2005; 11:365-9.
  • M.J. Rogers, S. Gordon, H.L. Benford, F.P. Coxon, S.P. Luckman, J. Monkkonen, J.C. Frith. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000; 15: 2961-78.
  • R.F. Barghash, W.M Abdou. Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates: From Basic Science to Medicine. Curr Pharm Des. 2016.
  • R.H. Goodday. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw. Oral Maxillofac Surg Clin North Am. 2015; 27: 527-36. doi: 10.1016/j.coms.2015.06.006.
  • S. Reiss, D. Sultan. Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis. N Y State Dent J. 2015 Nov; 81:30-3.
  • S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, B. Mehrotra; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Oral Maxillofac Surg. 2009; 67: 2-12. doi: 10.1016/j.joms.2009.01.009.
Datuen iturria: Dialnet